Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment

Sorafenib, a multi-targeted kinase inhibitor, is the current standard systemic treatment for advanced hepatocellular carcinoma. Sorafenib has anti-angiogenic and anti-proliferative properties and is also known to favor anti-tumor T cell responses by reducing the population of immunosuppressive cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrecko, Sindy, Guenat, David, Mercier-Letondal, Patricia, Faucheu, Hugues, Dosset, Magalie, Royer, Bernard, Galaine, Jeanne, Boidot, Romain, Kim, Stefano, Jary, Marine, Adotévi, Olivier, Borg, Christophe, Godet, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226040/
https://www.ncbi.nlm.nih.gov/pubmed/30459932
http://dx.doi.org/10.18632/oncotarget.26247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226040/
https://www.ncbi.nlm.nih.gov/pubmed/30459932
http://dx.doi.org/10.18632/oncotarget.26247

Ejemplares similares